A multicenter randomized controlled phase II study of 81 patients with EGFR T90M mutation in NSCLC, including 41 patients receiving osimertinib and 40 patients receiving osimertinib plus bevacizumab, showed that the ORR of osimertinib plus bevacizumab was superior to that of osimertinib monotherapy(68% vs. 54%). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.